Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Upadacitinib · Rinvoq, ABT-494

Small molecule · Inhibitor of JAK1 and JAK2 · developed by Abbvie

Approved FDA, Aug 2019

ABBV Developer

1 Registered trials

What is Upadacitinib?

Upadacitinib is an oral JAK inhibitor that blocks JAK1 and JAK2 with greater potency than JAK3 and TYK2, preventing STAT phosphorylation and downstream signaling.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Rinvoq, ABT-494
Drug type: Small molecule
Targets: JAK1, JAK2, JAK3 (secondary target), TYK2 (secondary target)
Mechanism: Inhibitor of JAK1 and JAK2
Pathways: JAK/STAT signaling, STAT phosphorylation
Therapy area: Gastroenterology
Developer: Abbvie (ABBV)
FDA status: Approved as Rinvoq (August 16, 2019), NDA211675 · FDA label
UNII: 4RA0KN46E0

✅ FDA-approved uses

Rheumatoid arthritis
Psoriatic arthritis
Atopic dermatitis
Ulcerative colitis
Crohn's disease

From the indications section of the FDA label (version of Jun 30, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07502339	Phase 4	UC - Ulcerative Colitis	Not yet recruiting	ABBV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

UC - Ulcerative Colitis

Other drugs acting on JAK1 / JAK2

Baricitinib FDA approved Fedratinib FDA approved Filgotinib Phase 3 LY5830966 Phase 1

More from Abbvie

Adalimumab FDA approved Atogepant FDA approved Pivekimab Sunirine FDA approved Risankizumab FDA approved Telisotuzumab Vedotin FDA approved Venetoclax FDA approved ABBV-1042 Phase 1 ABBV-291 Phase 1 ABBV-295 Phase 2 ABBV-313 Phase 1 ABBV-324 Phase 1 ABBV-438 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABBV page.

Follow ABBV, the company behind Upadacitinib

See ABBV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABBV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z